This article is a follow up to my May 23 article on T2 Biosystems. I previously provided an analysis of TTOO’s toxic credit agreement and unachievable revenue guidance. Since then, the company has lowered its revenue guidance and the stock has fallen more than 60%, including a 59% drop the day after the company reported earnings. However, the stock has recently rallied because of a press release disclosing that the Center for Medicare & Medicaid Services (CMS) has granted approval for a New Technology Add-On Payment (NTAP) for the T2Bacteria Panel for FY2020, allowing